Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
15:13:06 EDT Thu 02 May 2024
Enter Symbol
or Name
USA
CA



News for U:ABEO from 2023-05-03 to 2024-05-02 - 26 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-22 16:05U:ABEONews ReleaseAbeona Therapeutics Provides Regulatory Update on Pz-cel
2024-04-01 08:30U:ABEONews ReleaseAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-18 07:30U:ABEONews ReleaseAbeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
2024-03-05 07:30U:ABEONews ReleaseAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-01 16:05U:ABEONews ReleaseAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-01 07:30U:ABEONews ReleaseAbeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
2024-01-08 07:30U:ABEONews ReleaseAbeona Therapeutics Announces $50 Million Credit Facility
2023-12-15 07:30U:ABEONews ReleaseAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-27 07:30U:ABEONews ReleaseAbeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
2023-11-13 07:30U:ABEONews ReleaseAbeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
2023-11-01 07:30U:ABEONews ReleaseAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-26 07:30U:ABEONews ReleaseAbeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
2023-09-12 07:30U:ABEONews ReleaseAbeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
2023-09-07 07:30U:ABEONews ReleaseAbeona Therapeutics Announces Participation in Upcoming Investor Conferences
2023-08-30 07:30U:ABEONews ReleaseAbeona Therapeutics Announces Positive Pre-BLA Meeting with FDA for EB-101 and Plans for BLA Submission
2023-08-08 07:30U:ABEONews ReleaseAbeona Therapeutics Reports Second Quarter 2023 Financial Results
2023-07-28 07:30U:ABEONews ReleaseAbeona Therapeutics Announces Submission of Briefing Package for Pre-Biologics License Application (BLA) Meeting with FDA in August 2023
2023-07-19 08:30U:ABEONews ReleaseAbeona Therapeutics Joins Rare Disease Company Coalition
2023-07-07 08:30U:ABEONews ReleaseAbeona Therapeutics Announces Closing of $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2023-07-03 08:45U:ABEONews ReleaseAbeona Therapeutics Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
2023-06-09 07:30U:ABEONews ReleaseAbeona Therapeutics Announces Regulatory Update on Biologics License Application (BLA) for EB-101
2023-06-01 07:30U:ABEONews ReleaseAbeona Therapeutics to Present at the Jefferies Healthcare Conference
2023-05-22 07:30U:ABEONews ReleaseAbeona Therapeutics Announces Date Change for First Quarter 2023 Portfolio Update Conference Call to May 24, 2023
2023-05-16 09:00U:ABEONews ReleaseAbeona Therapeutics Announces New Preclinical Data from its AAV Ophthalmology Program at the 26th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
2023-05-11 07:30U:ABEONews ReleaseAbeona Therapeutics Reports First Quarter 2023 Financial Results
2023-05-11 07:00U:ABEONews ReleaseAbeona Therapeutics Announces Additional Phase 3 VIITAL ¢ „ ¢ Study Results for EB-101 Presented at the International Societies for Investigative Dermatology 2023 Meeting